Clinical Trials for Mesothelioma Patients—Gene Therapy for Pleural Malignancies: Criteria

Read the criteria for a current clinical trial on gene therapy being conducted on patients with advanced cancer or malignant mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only. This trial is currently only being conducted in Switzerland.

Inclusion Criteria:

• pathologically documented malignant pleural effusion from malignant mesothelioma or, metastatic from primary lung, breast, gastrointestinal, genitourinary, melanoma, or sarcoma

• must have evaluable disease

• must have ECOG performance status of 0 or 1

• must have pleural space involved with tumor accessible for pleural catheter

• must have FEV1 > 1 liter or 40% of predicted value

• must have completed radiotherapy and/or treatment with chemotherapy, cytotoxic, or immunologic agents 4 weeks prior to dosing with BG00001

Exclusion Criteria:

• malignant pleural effusions secondary to lymphoma

• rapidly re-accumulating, symptomatic malignant pleural effusions that require immediate mechanical or chemical pleurodesis for palliation

• presence of known untreated brain metastases

• use of concurrent systemic steroids or immunosuppressants Courtesy of ClinicalTrials.gov, a service of the U.S. National Institutes of Health